Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients

Prostate

Volumn 75, Issue 12, 2015, Pages 1312-1321

  Li, Qinlong ^a   Li, Quanlin ^a   Nuccio, Jill ^b   Liu, Chunyan ^a   Duan, Peng ^a   Wang, Ruoxiang ^a   Jones, Lawrence W ^b   Chung, Leland W K ^a   Zhau, Haiyen E ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

dormant cells; metastasis initiating cells; multiplexed quantum dot labeling; prostate cancer patient survival; RANK signaling

Indexed keywords

NEUROPILIN 1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCATTER FACTOR RECEPTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; NATRIURETIC PEPTIDE RECEPTOR A; OSTEOCLAST DIFFERENTIATION FACTOR; QUANTUM DOT;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL COUNT; CELL LABELING; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS INITIATING CELL; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL PREDICTION; VERY ELDERLY; BONE NEOPLASMS; DISEASE COURSE; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SURVIVAL RATE; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-MET; QUANTUM DOTS; RANK LIGAND; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 84937520173     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23011     Document Type: Article

References (29)

1. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM,. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290-1314.
2. Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW,. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr-Relat Cancer 2014; 21: 311-326.
3. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW,. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 2005; 65: 2303-2313.
4. Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LW,. Beta2-Microglobulin-mediated signaling as a target for cancer therapy. Anti-Cancer Agents Med Chem 2014; 14: 343-352.
5. Chu GC, Chung LW,. RANK-mediated signaling network and cancer metastasis. Cancer Metast Rev 2014; 33: 497-509.
6. Chung LW, Huang WC, Sung SY, Wu D, Odero-Marah V, Nomura T, Shigemura K, Miyagi T, Seo S, Chi C, Molitierno J, Elmore J, Anderson C, Isotani S, Edlund M, Hsieh CL, Wang R, Shehata B, Zhau HE,. Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer 2006; 5: 162-170.
7. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R,. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 2010; 21: 26-32.
8. Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LW, Zhau HE,. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PloS ONE 2011; 6: e28670.
9. Hu P, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE,. Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: An interracial comparative study. PloS ONE 2013; 8: e73081.
10. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE, Chung LW,. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 2008; 18: 858-870.
11. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW,. Epithelial to mesenchymal transition (EMT) in human prostate cancer: Lessons learned from ARCaP model. Clin Exp Metastas 2008; 25: 601-610.
12. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW, Zhau HE,. Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. The Prostate 2006; 66: 1664-1673.
13. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW,. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996; 93: 15152-15157.
14. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL,. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-538.
15. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM,. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
16. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM,. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323.
17. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ,. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
18. Duheron V, Hess E, Duval M, Decossas M, Castaneda B, Klopper JE, Amoasii L, Barbaroux JB, Williams IR, Yagita H, Penninger J, Choi Y, Lezot F, Groves R, Paus R, Mueller CG,. Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci USA 2011; 108: 5342-5347.
19. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE,. Control of mammary stem cell function by steroid hormone signalling. Nature 2010; 465: 798-802.
20. Sigl V, Penninger JM,. RANKL/RANK-from bone physiology to breast cancer. Cytokine Growth Factor Rev 2014; 25: 205-214.
21. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM,. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010; 468: 98-102.
22. Blake ML, Tometsko M, Miller R, Jones JC, Dougall WC,. RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastas 2014; 31: 233-245.
23. Garraway IP., Targeting the RANKL pathway: Putting the brakes on prostate cancer progression in bone. J Clin Oncol 2013; 31: 3838-3840.
24. Bonkhoff H., Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status. The Prostate Supplement 1998; 8: 18-22.
25. Bonkhoff H., Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001; 12: S141-S144.
26. Terry S, Beltran H,. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 2014; 4: 60.
27. Crea F, Danesi R, Farrar WL,. Cancer stem cell epigenetics and chemoresistance. Epigenomics 2009; 1: 63-79.
28. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat rev Cancer 2005; 5: 275-284.
29. Yan J, Tang D., Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response. Exp Cell Res 2014; 328: 132-42.